The Pharma Data

DECEMBER 3, 2020

TWO: 4162) announced today that it has entered into a Collaboration and License Agreement with UK-based Sentinel Oncology Limited for advancing the new drug development of SOL-578 , a Checkpoint Kinase 1 (Chk1) inhibitor, under which PharmaEngine will fund the IND enabling studies for SOL-578. TAIPEI , Dec. PharmaEngine, Inc.

Licensing 52

Licensing Licensing DNA Regulations 52

Drug Target Review

APRIL 23, 2024

The process of drug discovery is lengthy, and it can take 2-5 years on average to reach the preclinical phase. 1 To overcome the bottleneck of synthesising compounds of interest and forming derivatives for lead optimisation, in silico methods are being increasingly used in drug discovery workflows to drive efficiency. billion by 2031.

Licensing 100

Licensing Licensing Drug Development Drugs 100

The Pharma Data

JUNE 2, 2022

Boehringer Ingelheim and the Agency for Science, Technology and Research (A*STAR) today announced a global licensing agreement under which Boehringer Ingelheim will obtain exclusive worldwide rights to research, develop and commercialize products based on a panel of innovative, tumor-specific antibodies from A*STAR.

Licensing 52

Licensing Licensing Therapies Science 52

Drug Patent Watch

DECEMBER 18, 2024

Drug patent prosecution is a complex and critical process that can make or break the success of a new medication. As a business professional in the pharmaceutical industry, understanding and implementing effective strategies for drug patent prosecution can be the difference between market domination and missed opportunities.

Pharmaceuticals 94

Pharmaceuticals Drugs Drug Development Pharmaceutical Companies 94

Perficient: Drug Development

JANUARY 19, 2024

If you want to reduce capital and operational expenditures, speed time to market, and improve scalability, elasticity, security, and compliance, you should consider moving your on-premises IBM Sterling application to IBM supported native SaaS or other cloud solutions which best suits your business.

Compliance 118

Compliance Marketing Licensing Licensing 118

Predictive Oncology

MARCH 17, 2023

Cancer Research Horizons to incorporate PEDAL into future drug discovery processes to enable drug development on a global scale 11 marketed drugs 2nd largest oncology out-licensor globally 150+ active licenses 160+ new drugs into early-phase clinical trials $647 million revenue from royalties & IP $2.8

Research 52

Research Clinical Trials Licensing Licensing 52

Predictive Oncology

MARCH 21, 2023

Pamela Bush of Predictive Oncology discuss the potential impact of their collaboration and how it can advance cancer drug development.

Research 52

Research Licensing Licensing Drugs 52

DrugBank

OCTOBER 4, 2024

This involves assessing the strength and breadth of patents, evaluating the potential for future patent challenges, and analyzing the value derived from licensing agreements and royalty streams. billion acquisition of Grail , a cancer-detection test developer.

Pharmaceuticals 80

Pharmaceuticals Pharmaceutical Companies Therapies Marketing 80

The Pharma Data

OCTOBER 29, 2020

Tokyo, Japan) today announced that the European Medicines Agency (EMA) has confirmed it has accepted for review, following a standard timetable, the Marketing Authorization Application (MAA) for aducanumab, an investigational treatment for Alzheimer’s disease. have collaborated on the development and commercialization of aducanumab globally.

Disease 40

Disease Marketing Clinical Trials Treatment 40

LifeSciVC

JANUARY 16, 2024

These are incredible forecasts and CAGRs, which if we assume directionally correct, rely not only on steady growth for approved therapies but also a substantial success rate of, and continued investment in, the development pipeline. recent announcements from Merck and Sanofi for obesity and broader metabolic disease). Join the club.

Small Molecule 137

Small Molecule Trials Therapies Disease 137

Molecule Blog

AUGUST 6, 2021

An Open Bazaar for Drug Development: Molecule Protocol The complexity of biopharma IP deals When examining the transactional market for biopharma IP, one aspect becomes immediately obvious: IP is not sold in a simple purchase agreement like houses, cars or other physical objects. To achieve this, Molecule chose to use Arweave.

Licensing 52

Licensing Licensing Marketing Research 52

Perficient: Drug Development

SEPTEMBER 19, 2023

Increased Capabilities for Marketing Cloud and Commerce Cloud Salesforce introduced 26 generative AI capabilities between Marketing Cloud and Commerce Cloud, 14 of which are in GA now, with an additional 14 to arrive by the end of 2024.

Licensing 59

Licensing Licensing Production Marketing 59

Perficient: Drug Development

OCTOBER 27, 2023

Spartacus is an open-source JavaScript framework developed by SAP for building modern, responsive, and feature-rich e-commerce storefronts. The Composable Storefront emerged as an ideal solution for expedited market entry. This solution reduces time to market for SAP Commerce new implementations, upgrades, and migrations.

Compliance 105

Compliance Licensing Licensing Marketing 105

Perficient: Drug Development

NOVEMBER 10, 2023

Depending on the size of the team and anticipated activity within a program, additional RDEs can also be provisioned, however, this may come at an additional licensing cost from Adobe. Creating an Rapid Development Environment The RDE can be provisioned with a Program via Cloud Manager in AEM as a Cloud Service.

Packaging 105

Packaging Licensing Licensing International 105

Perficient: Drug Development

OCTOBER 22, 2024

A prominent labor union representing a large number of educators in a major metropolitan public school system recognized this need and partnered with Perficient to implement a scalable Salesforce Marketing Cloud Personalization solution. What is Marketing Cloud Personalization? The team was amazing from start to finish.

Marketing 52

Marketing Nurses Licensing Licensing 52

FDA Law Blog: Biosimilars

SEPTEMBER 18, 2024

That clause excludes those ingredients that were first marketed as drug ingredients. However, FDA’s interpretation creates that exact risk for a dietary supplement manufacturer who invests in development of a dietary supplement.

Production 59

Production FDA Licensing Licensing 59

The Pharma Data

AUGUST 21, 2020

Eli Lilly, on the heels of detailing a clinical win in China for PD-1 inhibitor Tyvyt, has decided to take a bigger stake in the drug developed by partner Innovent Biologics in an expanded deal that could vault it into the lucrative—yet ultra-competitive—U.S. lung cancer market. market, with Merck & Co.’s

Licensing 52

Licensing Licensing FDA Therapies 52

Crown Bioscience

MAY 4, 2021

Among the 180+ cancer drugs approved by the FDA since 1995, only 14 have been approved for pediatric use, with another 26 used off-label (i.e. used in a way that is not described in the license), and only three drugs have been approved exclusively for use in children.

Research 52

Research Pharmaceutical Companies Licensing Licensing 52

Molecule Blog

AUGUST 19, 2021

In drug development however, when a therapeutic is discovered, or research becomes more akin to product development, the source of funding must change. This is the point where no-strings-attached funding fails to link up with profit-motivated funding to turn a recent discovery into a product on the market.

Research 52

Research Licensing Licensing Drug Development 52

The Pharma Data

NOVEMBER 8, 2020

The Series B financing will be mainly used to conduct global clinical trials, research and development, and product in-licensing activities. Inmagene is a leading drug development company focused on immunology-related therapeutic areas. To date, Inmagene has raised over $40 million financing.

Clinical Trials 40

Clinical Trials Licensing Licensing Drug Development 40

Molecule Blog

JANUARY 9, 2023

IP-NFTs upgrade our legacy intellectual system by unifying IP (patents, legal), underlying data (through decentralized storage and access control), and economics (royalties, license fees, sales) into one programmable, transactable, digital unit. ‍ How will IP-NFTs enable drug development in the future?

Research 52

Research Licensing Licensing Science 52

Drug Target Review

AUGUST 9, 2024

Knowing and formulating the drug’s solubility, stability and particle size through design and addition of excipients is a continuous process throughout drug development. 1 Challenges in drug formulation Developing a successful drug formulation is fraught with challenges.

Science 59

Science Drugs Compliance Drug Development 59

The Pharma Data

JANUARY 25, 2021

Ambulero holds an exclusive license from the University of Miami to develop and commercialize research from the laboratories of Drs. As part of the investment, Ambulero and Orphinic formed a Polish subsidiary (Ambulero Sp. that will lead clinical testing of a novel gene therapy for a serious vascular disease in Europe.

Therapies 52

Therapies Disease Licensing Licensing 52

Codon

SEPTEMBER 29, 2024

It wasn’t a silver bullet to the hard problem of drug development, but it wasn’t too far off either. At best, the corporations with the best models released weak versions to the public under non-commercial licenses. A flurry of new, promising therapeutic targets arose. Subscribe to Asimov Press.

Engineering 131

Engineering Virus DNA Therapies 131

The Pharma Data

JUNE 28, 2021

The companies acquired by Bayer, Noria and PSMA Therapeutics, have exclusive world-wide rights to technology licensed from Weill Cornell Medicine (New York, NY, USA) and Johns Hopkins University (Baltimore, MD, USA). Noria was founded by Dr. John Babich, Chief, Radiopharmaceutical Sciences in Radiology at Weill Cornell Medicine.

Small Molecule 52

Small Molecule Licensing Licensing Therapies 52

Drug Target Review

OCTOBER 14, 2024

Wilkie’s background as a biochemist and his time at Merck, a leading pharmaceutical company, shaped his early understanding of drug development and business strategy. As someone who describes himself as an “enthusiastic sceptic,” Wilkie is cautious but hopeful about the potential of AI in drug development. “I

Science 52

Science Pharmaceutical Companies Drug Development Pharmaceuticals 52

Codon

FEBRUARY 13, 2024

Phage-based products have been licensed for use as antibacterial agents in the sanitation , food production , and animal health industries. Crucially, it could also make them easier to license as therapeutic agents. There is also a growing body of successful treatments in the U.S., Phage therapies are sold at a pharmacy in Georgia.

Therapies 116

Therapies Virus DNA Clinical Trials 116

Perficient: Drug Development

SEPTEMBER 11, 2023

Usually, Sitecore Headless Services can be implemented using the current licensing model, providing a seamless transition for existing Sitecore users, however we have seen clients on perpetual licenses need to negotiate with Sitecore to add this capability to their license. XM Cloud is where Sitecore is innovating.

Licensing 52

Licensing Licensing Packaging Marketing 52

Alta Sciences

DECEMBER 14, 2023

Regulatory Excellence - Licenses for Schedule I through IV drug substances. Clinical Supply Manufacturing Integration with our manufacturing team, ensuring flexibility and adaptability to meet the evolving needs of your studies throughout your drug development program or study. 24/7 monitoring of temperature and humidity.

Compounding Pharmacies 40

Compounding Pharmacies Pharmacy Clinical Pharmacology Clinical Supply 40

The Premier Consulting Blog

NOVEMBER 20, 2024

This process can be initiated during the review period of the biologics license application (BLA) or new drug application (NDA) prior to approval. ii When appropriately applied, concurrent validation provides a powerful tool to address impractical limitations of bringing new drugs and biologics to market.

Small Molecule 52

Small Molecule Drugs FDA Production 52

The Pharma Data

JANUARY 13, 2021

14, 2021 /PRNewswire/ — MindMed (NEO: MMED), (OTCQB: MMEDF), (DE: MMQ), a leading psychedelic medicine biotech company today announced the addition of Robert Barrow , an accomplished pharmaceutical executive, as Chief Development Officer. We are excited to attract such top tier talent from the psychedelic drug development community.

Clinical Trials 52

Clinical Trials FDA Trials Production 52

Drug Target Review

NOVEMBER 25, 2024

I went on to complete my MBA and PhD at The Institute of Cancer Research (ICR) in drug development. The PI3K pathway is a master switch of cancer, but first-generation inhibitors are associated with numerous side effects and poor long-term safety, which led to their withdrawal from the market.

Treatment 52

Treatment Small Molecule Clinical Trials Trials 52

The Pharma Data

JANUARY 13, 2021

Fast Track designation facilitates the development and expedites the review of drugs that are intended to treat serious and life-threatening conditions and show the potential to fill an unmet medical need. Brilacidin for UP/UPS was licensed to Alfasigma S.p.A.

Clinical Trials 52

Clinical Trials Trials Treatment Pharmaceuticals 52

Perficient: Drug Development

FEBRUARY 14, 2024

But there’s one more type of training your healthcare content strategists and marketers need that you’re (probably) not doing: healthcare writing training. The skills that often are part of successful digital marketing in other areas of commerce don’t always translate exactly to healthcare marketing. And it’s not you.

Engineering 52

Engineering International Marketing Licensing 52

Perficient: Drug Development

JUNE 7, 2023

Magento offers powerful marketing, search engine optimization, and Catalog management tools. Magento is a largely customizable E-Commerce platform available under both open-source and marketable licenses. Salesforce is a popular CRM tool for support, deals, and marketing brigades worldwide. I hope it’s useful.

Licensing 52

Licensing Licensing Engineering Marketing 52

Drug Target Review

NOVEMBER 22, 2023

Whilst TGF-β is an attractive target for cancer therapy because of its critical role in promoting tumor aggressiveness, immune escape and resistance to therapy, activation of alternative resistance pathways has hindered drug development attempts in the past. Pancreatic cancer is a very difficult cancer to treat.

Licensing 52

Licensing Licensing Small Molecule Therapies 52

Perficient: Drug Development

FEBRUARY 9, 2024

It has the power to host petabytes of information in one place and push up actionable predictions, insights, and marketing segments to the core customer relationship management (CRM) system or just about any external system that can receive data. The marketing team has her in different marketing segments for each product line.

Marketing 59

Marketing Licensing Licensing Production 59